Most biotechs have long expensive trial phases to get through before they'll ever make a dime of revenue, and going public helps these companies raise the capital necessary to make it to solvency. $GAHC seems to following similar paths. $ENDV $KBIO
http://finance.yahoo.com/news/why-gahc-biotec...00077.html